8 active not recruiting. 8 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Active not recruiting 8 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Suppuration: new trials by email Literature Review of Suppuration trials Research Report on Suppuration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa Upadacitinib - Hidradenitis Suppurativa (Acne Inversa) | Phase 2 | Active not recruiting | Peking Union Medical College | 50 | 2026-07-01 | 2026-07-27 |
| Abdominal aBscess Catheter Sclerotherapy (ABCS) Catheter Sclerotherapy - Abdominal Abscess | Phase 1 / Phase 2 | Active not recruiting | University of Alabama at Birmingham | 60 | 2025-12-21 | 2026-09-24 |
| A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. Ritlecitinib, Placebo - Hidradenitis Suppurativa | Phase 2 | Active not recruiting | Pfizer | 128 | 2025-11-13 | 2026-10-20 |
| A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa BFB759, Placebo for BFB759 - Hidradenitis Suppurativa (HS) | Phase 2 / Phase 3 | Active not recruiting | Bluefin Biomedicine, Inc. | 210 | 2025-11-03 | 2026-10-14 |
| A Study With CIT-013 in HS Patients CIT-013 high dose, CIT-013 medium dose, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Active not recruiting | Citryll BV | 108 | 2025-10-31 | 2026-10-19 |
| Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) Tulisokibart, Placebo - Hidradenitis Suppurativa | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 149 | 2025-06-09 | 2026-10-02 |
| Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense Tibulizumab Dose A, Tibulizumab Dose B, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Active not recruiting | Zura Bio Inc | 247 | 2025-05-16 | 2026-10-19 |
| A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy Lutikizumab, Placebo - Hidradenitis Suppurativa | Phase 2 | Active not recruiting | AbbVie | 210 | 2021-12-28 | 2026-02-13 |
Hidradenitis Suppurativa (7) · Abdominal Abscess (1) · Acne Vulgaris (1) · Dermatitis (1) · Hidradenitis (1) · Skin Diseases (1) · Skin Diseases, Bacterial (1) · Sweat Gland Diseases (1)
Infections (8) · Bacterial Infections (7) · Bacterial Infections and Mycoses (7) · Skin Diseases, Infectious (7) · Skin and Connective Tissue Diseases (7) · Hidradenitis (6) · Skin Diseases (6) · Skin Diseases, Bacterial (6) · Sweat Gland Diseases (6) · Abscess (1) · Acneiform Eruptions (1) · Sebaceous Gland Diseases (1)
lutikizumab (1) · upadacitinib (1)
AbbVie (1) · Bluefin Biomedicine, Inc. (1) · Citryll BV (1) · Merck Sharp & Dohme LLC (1) · Peking Union Medical College (1) · Pfizer (1) · University of Alabama at Birmingham (1) · Zura Bio Inc (1)
Canada (6) · Germany (6) · Spain (6) · United States (6) · Poland (4) · Australia (2) · China (2) · Greece (2) · Japan (2) · Netherlands (2) · United Kingdom (2) · Argentina (1) · Bulgaria (1) · Chile (1) · Colombia (1)
Junaid Raja, MD, MSPH, FACP (1) · Maarten Kraan (1)
2025 (1)